Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution

Annals of Oncology

Volumn 29, Issue 3, 2018, Pages 563-572

  Venkatesan, S ^a,b   Rosenthal, R ^a   Kanu, N ^a   McGranahan, N ^a   Bartek, J ^c,d,e   Quezada, S A ^a   Hare, J ^f   Harris, R S ^g,h,i,j,k   Swanton, C ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^c DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^d SCIENCE FOR LIFE LABORATORY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^j Molecular Biology and Biophysics ^*  (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

APOBEC; Drug resistance; Human immunodeficiency virus; Immune escape; Intratumour heterogeneity

Indexed keywords

APOLIPOPROTEIN B MRNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE; CHEMOKINE RECEPTOR CCR5; PROGRAMMED DEATH 1 LIGAND 1;

CANCER PROGNOSIS; CELLULAR PARAMETERS; CHROMOSOMAL INSTABILITY; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE RESPONSE; DRUG RESISTANCE; GENETIC HETEROGENEITY; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS; HYPERMUTATION; HYPOMUTATION; MALIGNANT NEOPLASM; MUTAGENESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SUBCLONAL DIVERSITY; TUMOR ESCAPE; VIRAL INFECTIVITY FACTOR; VIRUS GENOME; VIRUS VIRULENCE; ANIMAL; ENZYMOLOGY; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL TOLERANCE; NEOPLASM; PHYSIOLOGY;

ANIMALS; APOBEC DEAMINASES; DRUG RESISTANCE; HIV; HIV INFECTIONS; HUMANS; IMMUNE TOLERANCE; MUTAGENESIS; NEOPLASMS;

EID: 85046094021     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdy003     Document Type: Review

References (90)

1. Nik-Zainal S, Alexandrov LB, Wedge DC et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149(5): 979-993.
2. Burns MB, Lackey L, Carpenter MA et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013; 494: 366-370.
3. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013; 45(9): 977-983.
4. Alexandrov LB, Nik-Zainal S, Wedge DC et al. Signatures of mutational processes in human cancer. Nature 2013; 500(7463): 415-421.
5. Roberts SA, Lawrence MS, Klimczak LJ et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45(9): 970-976.
6. Law EK, Sieuwerts AM, LaPara K et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2016; 2: e1601737.
7. Sieuwerts AM, Willis S, Burns MB et al. Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. Horm Cancer 2014; 5(6): 405-413.
8. Henderson S, Chakravarthy A, Su X et al. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 2014; 7: 1833-1841.
9. Jamal-Hanjani M, Wilson GA, McGranahan N et al. Tracking the evolution of non-small-cell lung cancer. N Engl J Med 2017; 376(22): 2109-2121.
10. Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services et al. Integrated genomic and molecular characterization of cervical cancer. Nature 2017; 543: 378-384.
11. de Bruin EC, McGranahan N, Mitter R et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251-256.
12. McGranahan N, Favero F, de Bruin EC et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci Transl Med 2015; 7: 283ra254.
13. Lefebvre C, Bachelot T, Filleron T et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med 2016; 13: e1002201.
14. Harris RS, Petersen-Mahrt SK, Neuberger MS. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002; 10(5): 1247-1253.
15. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418(6898): 646-650.
16. Harris RS, Dudley JP. APOBECs and virus restriction. Virology 2015; 479-480: 131-145.
17. Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol 2015; 16(6): 546-553.
18. Muramatsu M, Kinoshita K, Fagarasan S et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102(5): 553-563.
19. Navaratnam N, Morrison JR, Bhattacharya S et al. The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase. J Biol Chem 1993; 268(28): 20709-20712.
20. Severi F, Chicca A, Conticello SG. Analysis of reptilian APOBEC1 suggests that RNA editing may not be its ancestral function. Mol Biol Evol 2011; 28: 1125-1129.
21. Conticello SG. The AID/APOBEC family of nucleic acid mutators. Genome Biol 2008; 9(6): 229.
22. LaRue RS, Jónsson SR, Silverstein KA et al. The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals. BMC Mol Biol 2008; 9: 104.
23. Sawyer SL, Emerman M, Malik HS. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004; 2: E275.
24. Mangeat B, Turelli P, Caron G et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003; 424(6944): 99-103.
25. Zhang H, Yang B, Pomerantz RJ et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003; 424(6944): 94-98.
26. Harris RS, Bishop KN, Sheehy AM et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113(6): 803-809.
27. Weil AF, Ghosh D, Zhou Y et al. Uracil DNA glycosylase initiates degradation of HIV-1 cDNA containing misincorporated dUTP and prevents viral integration. Proc Natl Acad Sci U S A 2013; 110: E448-E457.
28. Holmes RK, Koning FA, Bishop KN, Malim MH. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 2007; 282: 2587-2595.
29. Refsland EW, Stenglein MD, Shindo K et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res 2010; 38(13): 4274-4284.
30. Koning FA, Newman EN, Kim EY et al. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009; 83: 9474-9485.
31. Swanton C, McGranahan N, Starrett GJ, Harris RS. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 2015; 5(7): 704-712.
32. Helleday T, Eshtad S, Nik-Zainal S. Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet 2014; 15: 585-598.
33. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 2014; 14(12): 786-800.
34. Zhu M, Wang Y, Wang C et al. The eQTL-missense polymorphisms of APOBEC3H are associated with lung cancer risk in a Han Chinese population. Sci Rep 2015; 5: 14969.
35. Starrett GJ, Luengas EM, McCann JL et al. The DNA cytosine deaminase APOBEC3H haplotype I likely contributes to breast and lung cancer mutagenesis. Nat Commun 2016; 7: 12918.
36. Rosenthal R, McGranahan N, Herrero J et al. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol 2016; 17: 31.
37. Faltas BM, Prandi D, Tagawa ST et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet 2016; 48: 1490-1499.
38. Kim EY, Lorenzo-Redondo R, Little SJ et al. Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection. PLoS Pathog 2014; 10: e1004281.
39. Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015; 13(9): e1002251.
40. Delviks-Frankenberry KA, Nikolaitchik OA, Burdick RC et al. Minimal contribution of APOBEC3-induced G-to-A hypermutation to HIV-1 recombination and genetic variation. PLoS Pathog 2016; 12(5): e1005646.
41. Wood N, Bhattacharya T, Keele BF et al. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog 2009; 5(5): e1000414.
42. Birkbak NJ, Eklund AC, Li Q et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011; 71(10): 3447-3452.
43. Andor N, Graham TA, Jansen M et al. Pan-cancer analysis of the extent and consequences of intratumor heterogeneity. Nat Med 2016; 22(1): 105-113.
44. Schwarz RF, Ng CKY, Cooke SL et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 2015; 12(2): e1001789.
45. Harris RS. Enhancing immunity to HIV through APOBEC. Nat Biotechnol 2008; 26(10): 1089-1090.
46. Compton AA, Emerman M. Convergence and divergence in the evolution of the APOBEC3G-Vif interaction reveal ancient origins of simian immunodeficiency viruses. PLoS Pathog 2013; 9: e1003135.
47. Nakano Y, Misawa N, Juarez-Fernandez G et al. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation. PLoS Pathog 2017; 13: e1006348.
48. Yu X, Yu Y, Liu B et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302: 1056-1060.
49. Mercenne G, Bernacchi S, Richer D et al. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Res 2010; 38(2): 633-646.
50. Anderson BD, Harris RS. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-beta/RUNX axis. Sci Adv 2015; 1: e1500296.
51. Squires K, MonajemiM, Woodworth CF et al. Impact of APOBEC mutations on CD8+T cell recognition of HIV epitopes varies depending on the restricting HLA. J Acquir Immune Defic Syndr 2015; 70(2): 172-178.
52. Sadler HA, Stenglein MD, Harris RS, Mansky LM. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol 2010; 84: 7396-7404.
53. Monajemi M, Woodworth CF, Zipperlen K et al. Positioning of APOBEC3G/F mutational hotspots in the human immunodeficiency virus genome favors reduced recognition by CD8+ T cells. PLoS One 2014; 9: e93428.
54. Greaves M, Maley CC. Clonal evolution in cancer. Nature 2012; 481(7381): 306-313.
55. Tsibris AM, Korber B, Arnaout R et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009; 4: e5683.
56. Todesco E, Surgers L, Marcelin AG et al. Presence of minority resistant variants after failure of a tenofovir, emtricitabine, and rilpivirine regimen. J Acquir Immune Defic Syndr 2016; 72: e43-e45.
57. Fourati S, Malet I, Binka M et al. Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals. AIDS 2010; 24(15): 2313-2321.
58. Kim EY, Bhattacharya T, Kunstman K et al. Human APOBEC3Gmediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol 2010; 84: 10402-10405.
59. Boichard A, Tsigelny IF, Kurzrock R. High expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations. Oncoimmunology 2017; 6: e1284719.
60. Gay CL, Bosch RJ, Ritz J et al. Clinical trial of the Anti-PD-L1 antibody BMS-936559 in HIV-1 infected participants on suppressive antiretroviral therapy. J Infect Dis 2017; 215(11): 1725-1733.
61. Strizki JM, Tremblay C, Xu S et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1. Antimicrob Agents Chemother 2005; 49: 4911-4919.
62. Fätkenheuer G, Nelson M, Lazzarin A et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359: 1442-1455.
63. Westby M, Lewis M, Whitcomb J et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-4920.
64. Schmitt MW, Loeb LA, Salk JJ. The influence of subclonal resistance mutations on targeted cancer therapy. Nat Rev Clin Oncol 2016; 13: 335-347.
65. Nikkilä J, Kumar R, Campbell J et al. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells. Br J Cancer 2017; 117: 113-123.
66. Akre MK, Starrett GJ, Quist JS et al. Mutation processes in 293-based clones overexpressing the DNA cytosine deaminase APOBEC3B. PLoS One 2016; 11(5): e0155391.
67. Caval V, Suspene R, Shapira M et al. A prevalent cancer susceptibility APOBEC3A hybrid allele bearing APOBEC3B 3'UTR enhances chromosomal DNA damage. Nat Commun 2014; 5: 5129.
68. Landry S, Narvaiza I, Linfesty DC, Weitzman MD. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 2011; 12(5): 444-450.
69. Green AM, Landry S, Budagyan K et al. APOBEC3A damages the cellular genome during DNA replication. Cell Cycle 2016; 15: 998-1008.
70. Pilzecker B, Buoninfante OA, Pritchard C et al. PrimPol prevents APOBEC/AID family mediated DNA mutagenesis. Nucleic Acids Res 2016; 44(10): 4734-4744.
71. Buisson R, Lawrence MS, Benes CH, Zou L. APOBEC3A and 3B activities render cancer cells susceptible to ATR inhibition. Cancer Res 2017; 77(17): 4567-4578.
72. Green AM, Budagyan K, Hayer KE et al. Cytosine deaminase APOBEC3A sensitizes leukemia cells to inhibition of the DNA replication checkpoint. Cancer Res 2017; 77(17): 4579-4588.
73. Kanu N, Cerone MA, Goh G et al. DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer. Genome Biol 2016; 17(1): 185.
74. Bartkova J, Horejsí Z, Koed K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434(7035): 864-870.
75. Bartkova J, Rezaei N, Liontos M et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
76. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damagemodel for cancer development. Science 2008; 319(5868): 1352-1355.
77. Burrell RA, McClelland SE, Endesfelder D et al. Replication stress links structural and numerical cancer chromosomal instability. Nature 2013; 494: 492-496.
78. McGranahan N, Furness AJS, Rosenthal R et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 2016; 351(6280): 1463-1469.
79. Anagnostou V, Smith KN, Forde PM et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 2017; 7: 264-276.
80. Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 2017; 355; doi: 10.1126/science.aaf8399.
81. Karn T, Jiang T, Hatzis C et al. Association between genomic metrics and immune infiltration in triple-negative breast cancer. JAMA Oncol 2017; 3(12): 1707-1711.
82. Leonard B, McCann JL, Starrett GJ et al. The PKC/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res 2015; 75(21): 4538-4547.
83. Li M, Shandilya SMD, Carpenter MA et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem Biol 2012; 7(3): 506-517.
84. Olson ME, Li M, Harris RS, Harki DA. Small-molecule APOBEC3G DNA cytosine deaminase inhibitors based on a 4-amino-1, 2, 4-triazole- 3-thiol scaffold. ChemMedChem 2013; 8: 112-117.
85. Olson ME, Abate-Pella D, Perkins AL et al. Oxidative reactivities of 2- furylquinolines: ubiquitous scaffolds in common high-throughput screening libraries. J Med Chem 2015; 58: 7419-7430.
86. Lerner SP, Robertson G, Kim J et al. Comprehensive molecular characterization and analysis ofmuscle-invasive urothelial carcinomas. J Clin Oncol 2017; 35: 4500-4500.
87. Glaser AP, Fantini D, Rimar KJ, Meeks JJ. APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response. bioRxiv 2017.
88. Hedegaard J, Lamy P, Nordentoft I et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell 2016; 30: 27-42.
89. Mullane SA, Werner L, Rosenberg J et al. Correlation of APOBEC MRNA expression with overall survival and PD-L1 expression in urothelial carcinoma. Sci Rep 2016; 6: 27702.
90. Leonard B, Starrett GJ, Maurer MJ et al. APOBEC3G expression correlates with T cell infiltration and improved clinical outcomes in highgrade serous ovarian carcinoma. Clin Cancer Res 2017; 22(18): 4746-4755.